billion dollar ai company was built on lies

Medv's $1.8 Billion Valuation Fueled by AI Claims [00:00]

• The video challenges the narrative presented in a New York Times article that propelled a company named Medv to a $1.8 billion valuation, primarily attributing its success to AI.
• Medv is a telehealth provider specializing in GLP-1 weight loss drugs.
• The article highlighted the company's rapid growth, with $400 million in sales in its first full year (2025) and an projected $1.8 billion for the current year.
• It also mentioned the company's operation with only two employees, framing it as a testament to AI's power in the modern age, echoing predictions from "AI bros" like Sam Altman.

On the surface, right, it seems like the American dream. A guy goes from not being very successful to all of a sudden out of nowhere he has this billion-dollar company all because he prompted you know Chad GBT or whatever.

Allegations of Deception and Misleading Practices [01:52]

• Behind the glossy portrayal, the video uncovers a series of alleged deceptions including shady billing, fake doctors, FDA warning letters, class-action lawsuits, fake before-and-after pictures, and fraudulent advertisements.
• The New York Times article is criticized for glossing over or omitting many of these crucial details.
• A significant portion of the video focuses on evidence uncovered by Futurism, which investigated Medv's practices.

Fabricated Customer Testimonials and Image Manipulation [03:03]

• Futurism's investigation found that Medv's website featured AI-generated photos and product images with AI-generated text.
• The company allegedly used fake before-and-after photos for weight loss.
• An example shows a photo of a Redditor who lost 35 lbs in a year; Medv allegedly used this image, digitally altered it to add glasses and a beard, named the person "Michael P," and claimed he lost 48 pounds in 5 months, increasing the weight loss and shortening the timeframe.
• In a further manipulation, a different photo of a different person was used for the same testimonial, yet the name and weight loss figures remained the same.
• These doctored images were hosted on Medv's own website, indicating direct company involvement rather than solely affiliate actions.
• Despite claims of fixing these issues, these photos were allegedly still present on the website as recently as March.

So, this whole thing is built on lies.

Use of Fake Doctors and AI-Generated Content in Ads [05:03]

• Beyond fake customer testimonials, Medv allegedly uses fake doctors in advertisements for their GLP-1 drugs.
• Meta ad library data reveals ads featuring individuals identified as "Dr. Sarah Martin," "Dr. Monica Ashford," and "Dr. Lena Fischer" promoting Medv.
• Some of these ads also reportedly use misleading before-and-after photos.
• A video testimonial from someone claiming to be a doctor trying a "Tzepide pen" is presented as AI-generated, with both the doctor and patient being fabricated.
• These practices are described as "scammy Facebook ads of fake doctor accounts showing you AI slop, fake patient testimonials."

It's just a bunch of scammy Facebook ads of fake doctor accounts showing you AI slop, fake patient testimonials.

Allegations of Ineffective and Unproven Treatments [06:25]

• The video discusses allegations from a class-action lawsuit filed against Open Health, Inc., a partner of Medv.
• It points out that while some doctors appearing on these sites might be real, their exact involvement is unclear, with one doctor explicitly denying any affiliation with Medv.
• A significant claim in the lawsuit is that a key compound sold, oral tirzepatide, is ineffective "snake oil."
• The class-action complaint alleges that oral tirzepatide is unapproved, lacks demonstrated absorption or efficacy, and is "pharmacologically inert when delivered via a pill."
• Eli Lilly, the manufacturer of tirzepatide, states there are no human studies for any oral tirzepatide product, suggesting that any company selling it is making unproven claims and experimenting on consumers.

The classaction complaint alleges that the oral tirzepatide is a product that's never been approved, has no demonstrated mechanism of absorption or efficacy, and functions as modern-day snake oil, a pharmacologically inert compound when delivered via a pill.

FDA Warning Letter and Customer Dissatisfaction [08:52]

• Medv has received a warning letter from the FDA, citing "false and misleading claims concerning compounded semaglutide and tirzepatide products."
• The video suggests that Medv exploited a loose regulatory environment to push AI-generated content and products with questionable efficacy.
• Numerous customer reviews are presented, where individuals report spending significant amounts of money ($2,000 mentioned) without losing weight or even gaining weight, with some being told that the oral formulation doesn't work and being switched to injections.
• Complaints include receiving "defective" products, medication being deemed ineffective, and not being informed about the ineffectiveness of oral treatments during appointments.
• Shady billing practices are also highlighted, including price doubling, charging credit cards without sending medication, and refusing refunds.

This is a really shady website that took advantage of a loose regulatory regime to shove down a bunch of AI slop down people's throats in order to get them to buy products that in some cases, according to the people who actually make the product, allegedly don't work in that form, or at least there's no evidence that it works.

Broader Implications for AI and Business Ethics [10:43]

• The case of Medv is presented as a warning sign about the future of AI, where fake doctors, fake reviews, and AI-generated testimonials can create a convincing illusion of success.
• The video concludes that the company's massive sales, while a financial success, were achieved through unethical and deceptive means, representing the "exact opposite of a success story."
• It emphasizes that how sales are achieved is as, if not more, important than the sales figures themselves.
• The work of Maggie Dup Prey for Futurism in 2025 is credited for its thorough investigation into these practices.

And maybe just as bad, some of the billing practices of course are shady, which is what you'd expect from a company like this.